What We're Reading: Page 166
Industry reads hand-picked by our editors
Dec 22, 2020
-
The Wall Street Journal
Hiring Frenzy for Pharmacists as Covid-19 Vaccines Roll Out
-
STAT
The most impressive biotech VCs of 2020
-
Science
Suspicions grow that nanoparticles in Pfizer's COVID-19 vaccine trigger rare allergic reactions
-
Endpoints News
Looking to build a 'dual sourcing' supply chain, WuXi Biologics shells out $183M for Bayer drug substance plant
Dec 21, 2020
Dec 18, 2020
-
Bloomberg
Moderna Ditches 400,000 Vaccine Doses But Still Set to Meet Goal
-
STAT
Former J&J exec sues for sexual discrimination and harassment
-
BioCentury
Realities of limited manufacturing capacity for COVID-19 vaccines hit Horizon's Tepezza launch
-
CNBC
Alphabet health company Verily raises $700 million
Dec 17, 2020
Dec 16, 2020
-
The New York Times
U.S. and Pfizer Are Negotiating Deal for More Vaccine Doses Next Year
-
FiercePharma
Novartis' heart failure med Entresto wins FDA panel backing for bigger patient group—but just how much bigger?
-
Reuters
WHO vaccine scheme risks failure, leaving poor countries no COVID shots until 2024
-
Endpoints News
After leaving Wall Street to launch a gene therapy upstart, Rachel McMinn nabs $115M to drive her first candidate to the clinic
Dec 15, 2020
-
STAT
Inside the frantic and secretive sprint to name the Covid-19 vaccines
-
POLITICO
Trump's drug cards clear key hurdle following pressure from White House
-
Endpoints News
AbbVie pulls the trigger on a Covid-19 antibody, going all in on a drug discovered by research alliance
-
Healthcare Dive
Hospitals allege HHS let pharmas evade 340B drug discount rules
Dec 14, 2020
-
The Atlantic
COVID-19 Changed Science Forever
-
The Wall Street Journal
How Pfizer Delivered a Covid Vaccine in Record Time: Crazy Deadlines, a Pushy CEO
-
Bloomberg
Glaxo Is Said to Bid $120 a Share for Eidos in Rival Offer
-
Boston Business Journal
Head of Mass. biotech industry group MassBio to step down
Previous
